Palvella Therapeutics Quarterly Cash Flow Statement
NASDAQ: PVLAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
138.77+7.43 (+5.66%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Palvella Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Palvella Therapeutics generated -$12.8 million of operating cash flow. That left free cash flow of -$12.8 million.
Summary generated from market data by MetaCap's automated system. Methodology
Palvella Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -21.87M | -15.77M | -12.71M | -11.35M | -9.47M | -8.19M | -3.95M | -6.78M | -4.17M | -2.54M | 38.65M | -10.75M |
| Net Income growth (YoY) | — | — | — | — | — | — | -110.22% | — | -204.93% | — | — | — |
| Depreciation & Amortization | — | — | — | — | — | — | — | 0 | 0 | -30.00K | -198.00K | 739.00K |
| Stock-Based Compensation | 5.16M | 3.38M | 2.08M | 1.79M | 1.43M | 1.09M | 268.00K | 199.00K | 217.00K | 146.00K | -2.29M | 966.00K |
| Change in Working Capital | 286.00K | 494.00K | 1.41M | -1.31M | 615.00K | 2.30M | -1.22M | 1.86M | 2.19M | -3.96M | — | -15.52M |
| Operating Cash Flow | -12.85M | -10.86M | -4.93M | -7.88M | -5.43M | -6.77M | -5.39M | -2.74M | -1.60M | -1.10M | 20.45M | -9.72M |
| Capital Expenditures | — | — | — | — | — | — | — | 0 | 0 | 0 | 13.00K | -69.00K |
| Investing Cash Flow | -7.03M | -55.44M | — | — | 0 | 0 | — | 142.00K | 2.18M | 9.00M | 3.45M | -1.98M |
| Financing Cash Flow | 1.28M | 214.73M | -49.00K | 242.00K | 349.00K | -1.20M | 74.78M | 2.41M | 9.89M | 0 | -14.78M | 0 |
| Net Change in Cash | -18.59M | 148.41M | -5.58M | -6.87M | -5.19M | -7.98M | 69.39M | -330.00K | 8.29M | -1.10M | -2.96M | -12.04M |
| Free Cash Flow | -12.85M | -10.86M | -4.93M | -7.88M | -5.43M | -6.77M | -5.39M | -2.74M | -1.60M | -1.10M | 20.46M | -9.79M |
This table shows 12 quarterly periods of Palvella Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow PVLA's reporting calendar. What is a cash flow statement?